Vazyme(SH:688105) Zhong Guo Jing Ji Wang·2025-12-09 06:44Core Viewpoint - The announcement from China Securities Index Co., Ltd. regarding the periodic adjustment of various indices, including the CSI 300, CSI 500, and CSI 1000, indicates significant changes in sample stocks, effective after market close on December 12, 2025 [1]. Group 1: Index Adjustments - The CSI 300 index will replace 11 sample stocks, the CSI 500 will replace 50, the CSI 1000 will replace 100, the CSI A50 will replace 4, the CSI A100 will replace 6, and the CSI A500 will replace 20 [1]. - Notably, NuoVivian (688105.SH) has been removed from the CSI 1000 index sample [2]. Group 2: NuoVivian Financial Performance - In 2024, NuoVivian reported a revenue of 1.378 billion yuan, a year-on-year increase of 7.15%, but a net loss attributable to shareholders of 18.09 million yuan, compared to a loss of 70.96 million yuan in the previous year [3]. - For the first three quarters of 2025, NuoVivian achieved a revenue of 0.952 billion yuan, a year-on-year decrease of 3.40%, with a net profit of 6.62 million yuan, down 63.57% [4]. - The net cash flow from operating activities for NuoVivian was 64.55 million yuan in the first three quarters of 2025, compared to a negative cash flow of 99.99 million yuan in the same period last year [4]. Group 3: IPO and Fundraising - NuoVivian was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on November 15, 2021, with an issuance of 40.01 million shares at a price of 55.00 yuan per share, raising a total of 2.201 billion yuan [4]. - The net amount raised after deducting issuance costs was 2.109 billion yuan, exceeding the original plan by 907 million yuan [4]. - The total issuance costs amounted to 91.38 million yuan, with the lead underwriter, Huatai United Securities, receiving 72.64 million yuan in fees [4].